Article Text

Download PDFPDF

12 Humanized CD200/CD200R mice as a tool for evaluating novel therapeutics
  1. Ruili Lv1,
  2. Chong Li1,
  3. Zhiyuan Shen1,
  4. Qiurong Wang2 and
  5. Yuelei Shen1
  1. 1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China
  2. 2Biocytogen Boston Corp., Waltham, MA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Tumor-associated myeloid cells (TAMCs) represent a diverse population of immune cells capable of regulating tumor growth and progression via tumor-specific inflammation. Targeting key pathways that drive inflammation in the tumor microenvironment (TME) via TAMCs is of intense therapeutic interest. In particular, the membrane glycoprotein, CD200, has been shown to be expressed in several cancers and relays an immunoregulatory signal via CD200R, which suppresses anti-tumor immune responses. Therefore, the interaction between CD200 and CD200R plays an important role in regulating the TME via TAMCs.

Methods To explore potential therapeutic strategies targeting CD200/CD200R, we generated a human CD200/CD200R knockout/knock-in in situ (B-hCD200/hCD200R) mouse model to evaluate the efficacy of anti-human CD200 antibodies. We used flow cytometry to assess CD200 and CD200R protein expression and compare immune cell percentages between B-hCD200/hCD200R and wild-type mice.

Results We confirmed human CD200 and CD200R protein expression in B-hCD200/hCD200R mice by flow cytometry. We next observed that the overall development, differentiation, and distribution of splenic and lymph node immune cells were similar between parental wild-type C57BL/6 and B-hCD200/hCD200R mice by flow cytometry.

Conclusions Our data demonstrates B-hCD200/hCD200R mice are a robust preclinical model for in vivo efficacy evaluation of therapeutic candidates.

Ethics Approval All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Biocytogen Beijing Co., Ltd.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.